These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
346 related articles for article (PubMed ID: 16211093)
1. Modulation of atherosclerosis in mice by Toll-like receptor 2. Mullick AE; Tobias PS; Curtiss LK J Clin Invest; 2005 Nov; 115(11):3149-56. PubMed ID: 16211093 [TBL] [Abstract][Full Text] [Related]
2. Specific loss of toll-like receptor 2 on bone marrow derived cells decreases atherosclerosis in LDL receptor null mice. Hasu M; Thabet M; Tam N; Whitman SC Can J Physiol Pharmacol; 2011 Oct; 89(10):737-42. PubMed ID: 21895526 [TBL] [Abstract][Full Text] [Related]
3. Increased endothelial expression of Toll-like receptor 2 at sites of disturbed blood flow exacerbates early atherogenic events. Mullick AE; Soldau K; Kiosses WB; Bell TA; Tobias PS; Curtiss LK J Exp Med; 2008 Feb; 205(2):373-83. PubMed ID: 18250194 [TBL] [Abstract][Full Text] [Related]
4. Insulin-degrading enzyme deficiency in bone marrow cells increases atherosclerosis in LDL receptor-deficient mice. Caravaggio JW; Hasu M; MacLaren R; Thabet M; Raizman JE; Veinot JP; Marcel YL; Milne RW; Whitman SC Cardiovasc Pathol; 2013; 22(6):458-64. PubMed ID: 23684818 [TBL] [Abstract][Full Text] [Related]
5. Atherosclerosis induced by endogenous and exogenous toll-like receptor (TLR)1 or TLR6 agonists. Curtiss LK; Black AS; Bonnet DJ; Tobias PS J Lipid Res; 2012 Oct; 53(10):2126-2132. PubMed ID: 22822027 [TBL] [Abstract][Full Text] [Related]
9. Bone marrow-derived multidrug resistance protein ABCB4 protects against atherosclerotic lesion development in LDL receptor knockout mice. Pennings M; Hildebrand RB; Ye D; Kunne C; Van Berkel TJ; Groen AK; Van Eck M Cardiovasc Res; 2007 Oct; 76(1):175-83. PubMed ID: 17560559 [TBL] [Abstract][Full Text] [Related]
10. Important role for bone marrow-derived cholesteryl ester transfer protein in lipoprotein cholesterol redistribution and atherosclerotic lesion development in LDL receptor knockout mice. Van Eck M; Ye D; Hildebrand RB; Kar Kruijt J; de Haan W; Hoekstra M; Rensen PC; Ehnholm C; Jauhiainen M; Van Berkel TJ Circ Res; 2007 Mar; 100(5):678-85. PubMed ID: 17293475 [TBL] [Abstract][Full Text] [Related]
11. An unexpected intriguing effect of Toll-like receptor regulator RP105 (CD180) on atherosclerosis formation with alterations on B-cell activation. Karper JC; de Jager SC; Ewing MM; de Vries MR; Bot I; van Santbrink PJ; Redeker A; Mallat Z; Binder CJ; Arens R; Jukema JW; Kuiper J; Quax PH Arterioscler Thromb Vasc Biol; 2013 Dec; 33(12):2810-7. PubMed ID: 24115036 [TBL] [Abstract][Full Text] [Related]
12. The toll of Toll-like receptors, especially toll-like receptor 2, on murine atherosclerosis. Curtiss LK; Tobias PS Curr Drug Targets; 2007 Dec; 8(12):1230-8. PubMed ID: 18220700 [TBL] [Abstract][Full Text] [Related]
14. Deficiency of HIF1α in Antigen-Presenting Cells Aggravates Atherosclerosis and Type 1 T-Helper Cell Responses in Mice. Chaudhari SM; Sluimer JC; Koch M; Theelen TL; Manthey HD; Busch M; Caballero-Franco C; Vogel F; Cochain C; Pelisek J; Daemen MJ; Lutz MB; Görlach A; Kissler S; Hermanns HM; Zernecke A Arterioscler Thromb Vasc Biol; 2015 Nov; 35(11):2316-25. PubMed ID: 26404487 [TBL] [Abstract][Full Text] [Related]
15. Atheroprotective potential of macrophage-derived phospholipid transfer protein in low-density lipoprotein receptor-deficient mice is overcome by apolipoprotein AI overexpression. Valenta DT; Ogier N; Bradshaw G; Black AS; Bonnet DJ; Lagrost L; Curtiss LK; Desrumaux CM Arterioscler Thromb Vasc Biol; 2006 Jul; 26(7):1572-8. PubMed ID: 16675720 [TBL] [Abstract][Full Text] [Related]
16. Nrf2 in bone marrow-derived cells positively contributes to the advanced stage of atherosclerotic plaque formation. Harada N; Ito K; Hosoya T; Mimura J; Maruyama A; Noguchi N; Yagami K; Morito N; Takahashi S; Maher JM; Yamamoto M; Itoh K Free Radic Biol Med; 2012 Dec; 53(12):2256-62. PubMed ID: 23051009 [TBL] [Abstract][Full Text] [Related]
17. Paradoxical Suppression of Atherosclerosis in the Absence of microRNA-146a. Cheng HS; Besla R; Li A; Chen Z; Shikatani EA; Nazari-Jahantigh M; Hammoutène A; Nguyen MA; Geoffrion M; Cai L; Khyzha N; Li T; MacParland SA; Husain M; Cybulsky MI; Boulanger CM; Temel RE; Schober A; Rayner KJ; Robbins CS; Fish JE Circ Res; 2017 Aug; 121(4):354-367. PubMed ID: 28637783 [TBL] [Abstract][Full Text] [Related]
18. Prolactin receptor antagonism uncouples lipids from atherosclerosis susceptibility. van der Sluis RJ; van den Aardweg T; Reuwer AQ; Twickler MT; Boutillon F; Van Eck M; Goffin V; Hoekstra M J Endocrinol; 2014 Sep; 222(3):341-50. PubMed ID: 25063756 [TBL] [Abstract][Full Text] [Related]
19. Dual role for scavenger receptor class B, type I on bone marrow-derived cells in atherosclerotic lesion development. Van Eck M; Bos IS; Hildebrand RB; Van Rij BT; Van Berkel TJ Am J Pathol; 2004 Sep; 165(3):785-94. PubMed ID: 15331403 [TBL] [Abstract][Full Text] [Related]